## Abstract ## Objective An international, non‐randomised study evaluated efficacy and safety of risperidone long‐acting injectable (RLAI) compared to previous treatment. To investigate generisability of the European data set to the UK subset safety and switching data are reported here. ## Method
AD2 Cost-Consequence Analysis of Switching From An Oral Antipsychotic To Long Acting Injectable Risperidone Among Patients With Schizophrenia
✍ Scribed by L. Degli Esposti; D. Sangiorgi; S. Buda
- Book ID
- 119309833
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 122 KB
- Volume
- 14
- Category
- Article
- ISSN
- 1098-3015
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## Objective To investigate changes in cognitive function and clinical features following a switch from oral atypical antipsychotics (AAPs) to long‐acting injectable risperidone (LAIR) in patients with schizophrenia. ## Methods Thirty‐six patients with schizophrenia treated with oral
## Abstract ## Objective This international, non‐randomised study evaluated maintained efficacy and safety of Risperidone Long‐Acting Injectable (RLAI) compared to previous medications. To investigate the possible effect of differences in national health care systems across Europe, the UK subset e